FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1972823712> ?p ?o ?g. }

• W1972823712 endingPage "1535" @default.
• W1972823712 startingPage "1528" @default.
• W1972823712 abstract "Between December 1985 and August 1988, there were 115 patients at 13 centers who were entered on a randomized comparison of tetracycline and bleomycin for treatment of malignant pleural effusions. Fifteen patients were not treated, primarily due to rapid progression of systemic cancer. Fifteen patients entered on a high-dose regimen of bleomycin (120 units) were excluded from this analysis (following early closure of that arm), leaving 85 patients randomized to low-dose bleomycin (60 units; 44 patients) or tetracycline (1 g; 41 patients). Patients were required to have a cytologically positive pleural effusion, good performance status (0, 1, or 2), lung reexpansion following tube thoracostomy with drainage rates of 100 ml/24 or less, no prior intrapleural therapy, no prior systemic bleomycin therapy, no chest irradiation, and no recent (four weeks) change in systemic therapy. A total of 11 patients (five with bleomycin and six with tetracycline) were not evaluable due to technical problems with tube drainage (one), loss to follow-up (two), sudden death due to pulmonary embolus (one), and rapid progression of systemic disease (seven). There were no clinically significant differences in demographic factors, primary site, performance status, or presence of metastases other than pleural effusion. Overall survival did not differ between the two groups. Median time to recurrence or progression of the effusion was 32 days for tetracycline-treated patients and at least 46 days for bleomycin-treated patients (p=0.037). The recurrence rate within 30 days of instillation was 36 percent (10/28) with bleomycin and 67 percent (18/27) with tetracycline (p=0.023) (not all patients were restudied in the first 30 days). By 90 days the corresponding recurrence rates were 30 percent (11/37) for bleomycin and 53 percent (19/36) for tetracycline (p=0.047). Toxicity was similar between groups. Between December 1985 and August 1988, there were 115 patients at 13 centers who were entered on a randomized comparison of tetracycline and bleomycin for treatment of malignant pleural effusions. Fifteen patients were not treated, primarily due to rapid progression of systemic cancer. Fifteen patients entered on a high-dose regimen of bleomycin (120 units) were excluded from this analysis (following early closure of that arm), leaving 85 patients randomized to low-dose bleomycin (60 units; 44 patients) or tetracycline (1 g; 41 patients). Patients were required to have a cytologically positive pleural effusion, good performance status (0, 1, or 2), lung reexpansion following tube thoracostomy with drainage rates of 100 ml/24 or less, no prior intrapleural therapy, no prior systemic bleomycin therapy, no chest irradiation, and no recent (four weeks) change in systemic therapy. A total of 11 patients (five with bleomycin and six with tetracycline) were not evaluable due to technical problems with tube drainage (one), loss to follow-up (two), sudden death due to pulmonary embolus (one), and rapid progression of systemic disease (seven). There were no clinically significant differences in demographic factors, primary site, performance status, or presence of metastases other than pleural effusion. Overall survival did not differ between the two groups. Median time to recurrence or progression of the effusion was 32 days for tetracycline-treated patients and at least 46 days for bleomycin-treated patients (p=0.037). The recurrence rate within 30 days of instillation was 36 percent (10/28) with bleomycin and 67 percent (18/27) with tetracycline (p=0.023) (not all patients were restudied in the first 30 days). By 90 days the corresponding recurrence rates were 30 percent (11/37) for bleomycin and 53 percent (19/36) for tetracycline (p=0.047). Toxicity was similar between groups. The Optimal Treatment of Malignant Pleural Effusions A Continuing DilemmaCHESTVol. 100Issue 6PreviewMalignant pleural effusions are a common and often morbid problem in patients with advanced cancer.1 The optimal treatment of malignant pleural effusions remains controversial. While nonsclerosing cytotoxic intrapleural chemotherapy has occasionally been used to treat both the effusion and the underlying malignancy,2 the usual approach is to inject a sclerosing agent into the pleural space after draining the effusion by tube thoracostomy. Tetracycline is the most widely accepted sclerosant, but many other agents have been used, attesting to the fact that no single agent is uniformly satisfactory. Full-Text PDF" @default.
• W1972823712 created "2016-06-24" @default.
• W1972823712 creator A5007313781 @default.
• W1972823712 creator A5039061943 @default.
• W1972823712 creator A5056499111 @default.
• W1972823712 creator A5057026118 @default.
• W1972823712 creator A5057916216 @default.
• W1972823712 creator A5074922602 @default.
• W1972823712 creator A5083238099 @default.
• W1972823712 creator A5083544763 @default.
• W1972823712 creator A5085785599 @default.
• W1972823712 date "1991-12-01" @default.
• W1972823712 modified "2023-09-23" @default.
• W1972823712 title "Intrapleural Therapy for Malignant Pleural Effusions" @default.
• W1972823712 cites W1529470903 @default.
• W1972823712 cites W1561758716 @default.
• W1972823712 cites W1963719018 @default.
• W1972823712 cites W1964330965 @default.
• W1972823712 cites W1965443619 @default.
• W1972823712 cites W1974378958 @default.
• W1972823712 cites W1998001626 @default.
• W1972823712 cites W2005075629 @default.
• W1972823712 cites W2014350288 @default.
• W1972823712 cites W2029916366 @default.
• W1972823712 cites W2033519665 @default.
• W1972823712 cites W2034054017 @default.
• W1972823712 cites W2057298118 @default.
• W1972823712 cites W2060027395 @default.
• W1972823712 cites W2066141860 @default.
• W1972823712 cites W2091716234 @default.
• W1972823712 cites W2135201682 @default.
• W1972823712 cites W2159575641 @default.
• W1972823712 cites W2413217386 @default.
• W1972823712 cites W4249225566 @default.
• W1972823712 doi "https://doi.org/10.1378/chest.100.6.1528" @default.
• W1972823712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1720370" @default.
• W1972823712 hasPublicationYear "1991" @default.
• W1972823712 type Work @default.
• W1972823712 sameAs 1972823712 @default.
• W1972823712 citedByCount "154" @default.
• W1972823712 countsByYear W19728237122012 @default.
• W1972823712 countsByYear W19728237122013 @default.
• W1972823712 countsByYear W19728237122014 @default.
• W1972823712 countsByYear W19728237122015 @default.
• W1972823712 countsByYear W19728237122016 @default.
• W1972823712 countsByYear W19728237122017 @default.
• W1972823712 countsByYear W19728237122018 @default.
• W1972823712 countsByYear W19728237122019 @default.
• W1972823712 countsByYear W19728237122020 @default.
• W1972823712 countsByYear W19728237122022 @default.
• W1972823712 crossrefType "journal-article" @default.
• W1972823712 hasAuthorship W1972823712A5007313781 @default.
• W1972823712 hasAuthorship W1972823712A5039061943 @default.
• W1972823712 hasAuthorship W1972823712A5056499111 @default.
• W1972823712 hasAuthorship W1972823712A5057026118 @default.
• W1972823712 hasAuthorship W1972823712A5057916216 @default.
• W1972823712 hasAuthorship W1972823712A5074922602 @default.
• W1972823712 hasAuthorship W1972823712A5083238099 @default.
• W1972823712 hasAuthorship W1972823712A5083544763 @default.
• W1972823712 hasAuthorship W1972823712A5085785599 @default.
• W1972823712 hasConcept C126322002 @default.
• W1972823712 hasConcept C141071460 @default.
• W1972823712 hasConcept C163430725 @default.
• W1972823712 hasConcept C2776178081 @default.
• W1972823712 hasConcept C2776232574 @default.
• W1972823712 hasConcept C2776517811 @default.
• W1972823712 hasConcept C2776694085 @default.
• W1972823712 hasConcept C2776974961 @default.
• W1972823712 hasConcept C2776979038 @default.
• W1972823712 hasConcept C2777063151 @default.
• W1972823712 hasConcept C2777714996 @default.
• W1972823712 hasConcept C2777799383 @default.
• W1972823712 hasConcept C2778329176 @default.
• W1972823712 hasConcept C2779634585 @default.
• W1972823712 hasConcept C2781413609 @default.
• W1972823712 hasConcept C71924100 @default.
• W1972823712 hasConcept C90924648 @default.
• W1972823712 hasConceptScore W1972823712C126322002 @default.
• W1972823712 hasConceptScore W1972823712C141071460 @default.
• W1972823712 hasConceptScore W1972823712C163430725 @default.
• W1972823712 hasConceptScore W1972823712C2776178081 @default.
• W1972823712 hasConceptScore W1972823712C2776232574 @default.
• W1972823712 hasConceptScore W1972823712C2776517811 @default.
• W1972823712 hasConceptScore W1972823712C2776694085 @default.
• W1972823712 hasConceptScore W1972823712C2776974961 @default.
• W1972823712 hasConceptScore W1972823712C2776979038 @default.
• W1972823712 hasConceptScore W1972823712C2777063151 @default.
• W1972823712 hasConceptScore W1972823712C2777714996 @default.
• W1972823712 hasConceptScore W1972823712C2777799383 @default.
• W1972823712 hasConceptScore W1972823712C2778329176 @default.
• W1972823712 hasConceptScore W1972823712C2779634585 @default.
• W1972823712 hasConceptScore W1972823712C2781413609 @default.
• W1972823712 hasConceptScore W1972823712C71924100 @default.
• W1972823712 hasConceptScore W1972823712C90924648 @default.
• W1972823712 hasIssue "6" @default.
• W1972823712 hasLocation W19728237121 @default.
• W1972823712 hasLocation W19728237122 @default.
• W1972823712 hasOpenAccess W1972823712 @default.

• next